This is why we classified patients with positive expression of FMC7, CD79b, CD22, and/or weak expression of CD5, CD19, and CD23, who were diagnosed with CLL, into the atypical group. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.